Rep. Jefferson Shreve Buys Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated NASDAQ: VRTX. In a filing disclosed on April 11th, the Representative disclosed that they had bought between $15,001 and $50,000 in Vertex Pharmaceuticals stock on March 13th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Harley-Davidson NYSE: HOG on 3/31/2025.
• Purchased $50,001 - $100,000 in shares of Block NYSE: XYZ on 3/31/2025.
• Sold $15,001 - $50,000 in shares of DuPont de Nemours NYSE: DD on 3/31/2025.
• Purchased $15,001 - $50,000 in shares of United Community Banks NASDAQ: UCB on 3/31/2025.
• Sold $15,001 - $50,000 in shares of IDEX NYSE: IEX on 3/31/2025.
• Purchased $15,001 - $50,000 in shares of HNI NYSE: HNI on 3/31/2025.
• Sold $50,001 - $100,000 in shares of ServiceNow NYSE: NOW on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Coinbase Global NASDAQ: COIN on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Constellation Energy NASDAQ: CEG on 3/31/2025.
• Sold $50,001 - $100,000 in shares of Simon Property Group NYSE: SPG on 3/31/2025.

Vertex Pharmaceuticals Trading Up 0.7 %

VRTX traded up $3.21 during trading on Friday, reaching $489.10. The company had a trading volume of 1,205,462 shares, compared to its average volume of 1,328,900. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The company has a market cap of $125.60 billion, a price-to-earnings ratio of -222.32, a PEG ratio of 2.11 and a beta of 0.50. The firm's 50-day simple moving average is $486.09 and its 200 day simple moving average is $465.07.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Royal Bank of Canada raised their price target on shares of Vertex Pharmaceuticals from $408.00 to $420.00 and gave the stock a "sector perform" rating in a report on Tuesday, April 1st. Cantor Fitzgerald reissued an "overweight" rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Wells Fargo & Company cut Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price objective for the company. in a research report on Thursday, January 30th. Finally, Canaccord Genuity Group raised Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and raised their price target for the stock from $408.00 to $424.00 in a research note on Tuesday, February 11th. Ten analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $512.41.

Insider Buying and Selling

In related news, EVP Ourania Tatsis sold 310 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total transaction of $142,547.30. Following the completion of the transaction, the executive vice president now directly owns 64,021 shares of the company's stock, valued at $29,438,776.43. This trade represents a 0.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP David Altshuler sold 3,231 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares in the company, valued at $13,256,000. This represents a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 4,315 shares of company stock worth $2,121,012 in the last 90 days. 0.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in VRTX. ABC Arbitrage SA acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $1,510,000. Czech National Bank raised its stake in shares of Vertex Pharmaceuticals by 6.2% in the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company's stock valued at $22,486,000 after buying an additional 3,260 shares in the last quarter. Highview Capital Management LLC DE boosted its position in shares of Vertex Pharmaceuticals by 1.8% during the 4th quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company's stock valued at $2,324,000 after acquiring an additional 102 shares in the last quarter. Davidson Investment Advisors increased its stake in Vertex Pharmaceuticals by 26.0% in the fourth quarter. Davidson Investment Advisors now owns 61,161 shares of the pharmaceutical company's stock valued at $24,630,000 after acquiring an additional 12,631 shares during the period. Finally, Jones Financial Companies Lllp raised its holdings in shares of Vertex Pharmaceuticals by 75.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company's stock worth $994,000 after buying an additional 1,062 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.